Related Experiment Video
Updated: Aug 8, 2026
Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)
Published on: January 20, 2010
Roquinimex inhibits dextran sodium sulfate-induced murine colitis
1Department of Surgery, Malmö University Hospital, Lund University, 20502 Malmö, Sweden.
Objective:
Roquinimex is a modulator of the immune system and has been shown to attenuate induction of several inflammatory and autoimmune diseases. The objective of the present study was to determine the efficacy of roquinimex in a model of murine colitis.
Materials And Methods:
For this purpose, Balb/c mice were exposed to 5% dextran sodium sulfate (DSS) in the drinking water for five to six days. Roquinimex (300 mg kg(-1) day(-1)) was administered by subcutaneous (s.c.) injection 3 days prior to and throughout the treatment period with DSS. In separate experiments, 300 mg kg(-1) day(-1) of roquinimex was given therapeutically after initiation of DSS challenge.
Results:
DSS provoked clinical signs of colitis, reduced crypt height (CH) and increased mucosal damage score (MDS) as analyzed by histology. In addition, challenge with DSS increased the colonic content of myeloperoxidase (MPO). Prophylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity.
Conclusions:
These findings suggest that roquinimex strongly inhibits murine colitis and may provide a novel pharmacological approach to treat inflammatory bowel disease.
Insights
Roquinimex effectively treats murine colitis by reducing inflammation and tissue damage. This immunomodulator shows promise as a novel therapeutic for inflammatory bowel disease.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Roquinimex is an immunomodulator with demonstrated efficacy in preclinical models of inflammatory and autoimmune diseases.
- Inflammatory bowel disease (IBD) encompasses chronic inflammatory conditions of the gastrointestinal tract, necessitating novel therapeutic strategies.
Purpose of the Study:
- To evaluate the therapeutic potential of roquinimex in a well-established model of murine colitis induced by dextran sodium sulfate (DSS).
Main Methods:
- Balb/c mice were administered 5% DSS in drinking water to induce colitis.
- Roquinimex was administered prophylactically (3 days prior to DSS) and therapeutically (after DSS challenge) via subcutaneous injection at 300 mg/kg/day.
- Colitis severity was assessed by clinical signs, histology (crypt height, mucosal damage score), and myeloperoxidase (MPO) activity.
Main Results:
- DSS induction led to significant clinical signs of colitis, reduced crypt height, increased mucosal damage, and elevated MPO levels.
- Prophylactic roquinimex administration significantly ameliorated clinical signs, reduced mucosal damage, preserved crypt height, and decreased MPO activity by over 50%.
- Therapeutic roquinimex treatment also significantly inhibited DSS-induced mucosal damage, crypt height reduction, and MPO activity.
Conclusions:
- Roquinimex demonstrates potent anti-colitic effects in a murine model, significantly reducing inflammation and tissue damage.
- These findings highlight roquinimex as a promising candidate for the pharmacological treatment of inflammatory bowel disease.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents